Retatrutide: Complete Guide to the Triple-Agonist Peptide

Retatrutide is a synthetic peptide that activates three key metabolic receptors:

• GLP-1 (glucagon-like peptide-1): Suppresses appetite, slows gastric emptying, improves insulin sensitivity — the same target as semaglutide
• GIP (glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and fat metabolism — also targeted by tirzepatide
• Glucagon receptor: Increases energy expenditure, promotes fat oxidation, and reduces liver fat — this is the novel third mechanism

By hitting all three receptors, retatrutide addresses weight loss from multiple angles: reducing food intake, improving metabolic efficiency, AND actively increasing calorie burn. No other approved or late-stage compound does all three.

The Phase 2 trial (published in The New England Journal of Medicine, 2023) enrolled 338 adults with obesity:

• 24.2% mean weight loss at 48 weeks (12 mg dose)
• 26% of participants lost more than 30% of body weight
• Significant reductions in liver fat (up to 42.9%)
• Improvements in HbA1c, triglycerides, and blood pressure

For context:

• Semaglutide (Wegovy): ~15% weight loss at 68 weeks
• Tirzepatide (Zepbound): ~22.5% at 72 weeks
• Retatrutide: ~24.2% at just 48 weeks

The glucagon component appears to be the differentiator — it increases resting energy expenditure by 100-200 kcal/day, meaning you burn more calories even at rest.

How does the triple agonist stack up against its predecessors?

Retatrutide's biggest advantage beyond raw weight loss numbers is its liver fat reduction — a critical factor for metabolic health that neither semaglutide nor tirzepatide addresses as effectively.

Based on Phase 2 trial data, retatrutide uses a dose escalation protocol:

• Weeks 1–4: Starting dose (typically 2 mg/week)
• Weeks 5–8: Mid-range escalation (4–8 mg/week)
• Weeks 9+: Target dose (8–12 mg/week)

Administration: Subcutaneous injection, once weekly. Same injection technique as semaglutide or tirzepatide. Rotation sites: abdomen, thigh, or upper arm.

Important: The 12 mg dose showed the best results in trials but also the highest side effect rate. The 8 mg dose offered a strong efficacy-to-tolerability balance.

Side effects are similar to other GLP-1 agonists but with some additional considerations:

Common (>10% of participants):

• Nausea (especially during dose escalation)
• Diarrhea
• Decreased appetite
• Vomiting
• Constipation

Less common:

• Increased heart rate (2–4 bpm average)
• Injection site reactions
• Dizziness

Glucagon-specific concerns: The glucagon component theoretically raises blood sugar, but in trials, the GLP-1 and GIP components counterbalanced this effect. However, people with diabetes need careful monitoring.

No serious safety signals emerged in Phase 2, but longer-term Phase 3 data is still being collected.

Eli Lilly initiated Phase 3 trials in late 2023 for both obesity and MASH (metabolic-associated steatohepatitis, formerly NAFLD). Estimated timelines:

• Phase 3 completion: Late 2025 to mid 2026
• FDA submission: Likely 2026
• Potential approval: Late 2026 to 2027

Research-grade retatrutide is available from peptide research suppliers, though quality and purity vary significantly. Third-party testing (HPLC/MS) is essential for any research compound.

Retatrutide represents the cutting edge of metabolic peptide research. Its triple-agonist mechanism delivers results that surpass both semaglutide and tirzepatide in early trials, while its liver fat reduction could make it the treatment of choice for MASH — a condition affecting an estimated 5% of adults globally.

The main caveats: it's still in Phase 3, long-term safety data is limited, and the side effect profile during dose escalation requires careful management. But the numbers speak for themselves — 24% weight loss in under a year is unprecedented.